Latest Pharma and Biotech News
Biotechnology
10 August 2026 Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire privately-held US biotech Actio Biosciences with the aim of expanding its epilepsy portfolio.
Today's issue
Refine search
Pharmaceutical
Tenax Therapeutics saw its shares plummet 90% to $1.38, after it announced disappointing top-line results from the Phase III LEVEL clinical trial evaluating TNX-103 (oral levosimendan) in patients with pulmonary hypertension (PH)- preserved ejection fraction (HFpEF). 11 August 2026
Biotechnology
French regenerative cell therapy developer CellProthera has announced the signing of a Memorandum of Understanding (MoU) with Alfresa Holding, one of Japan’s leading pharmaceutical distribution groups, to establish a strategic collaboration for the development and future distribution of its lead product candidate ProtheraCytes in Japan. 11 August 2026
Pharmaceutical
US clinical-stage biopharma Kailera Therapeutics, focused on elevating the next era of obesity care, today announced the appointment of Nur Nicholson as chief technology officer (CTO), effective August 31, 2026. 11 August 2026
Pharmaceutical
The next phase of competition in the HIV market will be defined not only by achieving viral suppression, but by improving treatment adherence, reducing medication burden and delivering more convenient treatment options, with long-acting therapies at the forefront. 11 August 2026
Pharmaceutical
Privately-held German biopharma company Isotope Technologies Munich (ITM) revealed that it has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application for 177Lu-edotreotide (ITM-11), an investigational agent for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 11 August 2026
Pharmaceutical
The US Food and Drug Administration (FDA) approved Foundayo (orforglipron) on April 1 this year, for adults with obesity or overweight with weight-related medical problems. USA-based pharma major Eli Lilly (NYSE: LLY) began accepting prescriptions through its own LillyDirect platform immediately, with shipping from April 6. Broad availability through US retail pharmacies and telehealth providers began on April 9. 11 August 2026
Biotechnology
London-based biotech firm Silence Therapeutics said on Monday that lead candidate divesiran met the primary endpoint of the Phase II SANRECO trial in polycythemia vera (PV), a rare blood cancer in which the bone marrow overproduces red blood cells. Shares rose sharply on the news, touching a 52-week high. 11 August 2026
Biotechnology
Swiss biotech firm MoonLake Immunotherapeutics said on Monday that sonelokimab met all clinical endpoints at week 16 in the Phase III IZAR-1 trial in psoriatic arthritis (PsA). Shares fell about 6% on the day, as the company held back the one comparison investors were waiting for. 11 August 2026
Biotechnology
Privately-held US biotech Avere Therapeutics, which is advancing oral therapies for interleukin (IL)-23 driven inflammatory diseases, has announced a $500 million private placement from a syndicate of leading healthcare investors. 11 August 2026
Pharmaceutical
Donald Trump signed an executive order on Monday recommending that American children be routinely immunized against 11 diseases rather than the 18 covered by the US Centers for Disease Control and Prevention's (CDC) 2024 schedule, and that the combined measles, mumps and rubella (MMR) vaccine be split into three single-disease shots. 11 August 2026
Pharmaceutical
Bristol Myers Squibb has announced the selection of Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3 billion investment designed to accelerate the delivery of next-generation medicines to patients. 11 August 2026
Pharmaceutical
The Organization of Pharmaceutical Producers of India (OPPI) is intensifying its dialogue with policymakers to establish a Regulatory Data Protection (RDP) regime in India. 11 August 2026
Biotechnology
US immunotherapy company ImmunityBio has announced that Dr Jim Yong Kim has joined the company as vice chairman. 11 August 2026
Biotechnology
Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire privately-held US biotech Actio Biosciences with the aim of expanding its epilepsy portfolio. 10 August 2026
Biotechnology
Shares of Canada’s AbCellera were up nearly 33% at $9.20 in pre-market activity today after it announced positive top-line results from the Phase II portion of its Phase I/II clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody. 10 August 2026
Biotechnology
French rare diseases company Innate Pharma (and Swedish Orphan Biovitrum (Sobi) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase III study in cutaneous T-cell lymphoma (CTCL). 10 August 2026
Biosimilars
South Korean biosimilar firm Samsung Bioepis, a wholly owned subsidiary of Samsung Epis Holdings, expects to put a pre-filled syringe version of its Eylea copy Opuviz (aflibercept) on the European market in the third quarter, a few months after launching the vial presentation into a field already thick with rivals. 10 August 2026
Biotechnology
US biotech BioMarin Pharmaceutical has pulled the plug on BMN 401, discontinuing the enzyme replacement therapy across all indications just over a year after it paid around $270 million to buy the asset along with its developer, Inozyme Pharma. 10 August 2026
Pharmaceutical
Danish-based, Swedish-listed biotech Saniona (OMX: SANION) said today that its UK partner AstronauTx has exercised an option to take exclusive worldwide rights to compounds emerging from the pair's ion channel collaboration, handing Saniona equity worth $5 million and keeping alive a milestone package of up to $172 million. 10 August 2026
Pharmaceutical
Spanish dermatology specialist Almirall today announced a collaboration and licensing agreement with Shenzhen CrystalO Biopharma Technology to jointly initiate an R&D collaboration for drug discovery in medical dermatology. 10 August 2026
All news
Pharmaceutical
US late clinical-stage pharma Altimmune, focused on serious liver diseases, yesterday announced positive top-line results from the RECLAIM Phase II trial evaluating pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol use disorder (AUD). 29 July 2026
Pharmaceutical
UK pharma major GSK is to build a major new global research and development center on the Cambridge Biomedical Campus, moving its UK R&D operations there and closing its long-standing site in Stevenage, Hertfordshire. The company will invest £400 million ($532 million) over three years. 29 July 2026
Pharmaceutical
Medicines regulators across major markets issued a mix of approvals, class-wide safety warnings, a product defect notification and consultation activity over the past week, spanning central nervous system, metabolic, ophthalmology and vaccine areas. 29 July 2026
Pharmaceutical
Privately held, US clinical-stage pharma Saol Therapeutics announced that the US Food and Drug Administration (FDA) has acknowledged the company's resubmission of its New Drug Application (NDA) for SL1009, sodium dichloroacetate (DCA). 29 July 2026
Pharmaceutical
The non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) market in India is entering a new phase, with awareness-driven strategies expected to play a pivotal role in improving diagnosis, treatment access, and patient outcomes. 29 July 2026
Pharmaceutical
UK pharma major GSK reported better-than-expected second-quarter 2026 results, helped by continued growth in Specialty Medicines and Vaccines, as it announced a three-year cost-saving program to fund increased investment in its late-stage pipeline. 28 July 2026
Pharmaceutical
ViiV Healthcare's two-drug HIV pill Dovato (dolutegravir/lamivudine) has matched the efficacy of Gilead's market-leading three-drug regimen Biktarvy in the first trial pitting the two directly against each other in patients starting treatment for the first time. The data, from the Phase IIIb VOGUE study, were unveiled this week at the AIDS 2026 conference in Rio de Janeiro, Brazil. 28 July 2026
Biotechnology
MapLight Therapeutics, a US biotech focused on central nervous system disorders, has reported a split verdict from its Phase II ZEPHYR trial in schizophrenia, with one dose of its experimental muscarinic drug hitting the mark and another falling short. 28 July 2026
Pharmaceutical
US obesity specialist Ambrosia Biosciences has strengthened its clinical and scientific ranks, naming cardiometabolic drug developer Linda Shapiro Manning as chief medical officer and adding obesity researcher Randy Seeley to its scientific advisory board. The privately held Boulder, Colorado firm is preparing to move its lead oral candidate into first human trials. 28 July 2026
Biotechnology
UK pharma major GSK today revealed that its licensor Hansoh Pharmaceutical has announced that ARTEMIS-011, its pivotal Phase III trial evaluating risvutatug rezetecan (Ris-Rez) in patients with osteosarcoma who have progressed or relapsed after receiving at least two prior lines of systemic therapy, met its primary endpoint of progression-free survival (PFS). 28 July 2026
Biotechnology
US late-stage biotech Claris Biotherapies today announced multiple key milestones, including the close of a $118 million Series B financing and key executive and board appointments. 28 July 2026
Biotechnology
USA-based cell therapy company Legend Biotech has named Alan Bash as interim chief executive after Ying Huang stepped down from the role and resigned from the board. 28 July 2026
Biotechnology
US biotech Apnimed has set the terms for its long-awaited initial public offering, seeking to raise up to $150 million as it prepares for a potential commercial launch of its lead obstructive sleep apnea (OSA) therapy, Oxnimbi (AD109). 28 July 2026
Biotechnology
Biotech company Capricor Therapeutics faces heightened regulatory uncertainty after US Food and Drug Administration (FDA) reviewers questioned whether its resubmitted Biologics License Application for deramiocel provides substantial evidence of effectiveness in cardiomyopathy in male patients with Duchenne muscular dystrophy. 28 July 2026
Biotechnology
US rare diseases company Sarepta Therapeutics has announced the appointment of Dr Michael Severino as chief executive (CEO), effective July 28, 2026. 28 July 2026
Biotechnology
China is emerging as a global biotechnology innovation hub, but its growing influence is facing political and regulatory scrutiny from the USA. The US policy response reflects concerns around its competitiveness and technological leadership, rather than the country’s scientific capability alone. 28 July 2026
Pharmaceutical
The US Food and Drug Administration’s (FDA) Oncology Center of Excellence has announced three final guidance documents intended to broaden eligibility criteria for participation in clinical trials of oncology drugs. 28 July 2026
Biotechnology
Spruce Biosciences has appointed Dr Adrian Quartel as chief medical officer (CMO), effective immediately. 28 July 2026
Pharmaceutical
Russia plans to focus on the design and production of fundamentally new drugs within the next several years, according to recent statements by Russia’s Prime Minister Mikhail Mishustin. 28 July 2026
Biotechnology
Cambridge, USA-based biotech Oak Hill Bio this morning announced plans to go public via a combination with RA Capital-backed special purpose acquisition company (SPAC) Research Alliance Corporation III. 27 July 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze